Immutep Limited

A$0.02As of Sun 8 Nov 2026, 12:00 UTC

ASX:IMMHealthcare

Country Australia

PE (Fwd) •••

TSR 10Y CAGR (24.45%)

Div yield —

ROE (77.31%)

Biotechnology

Beta (5Y) 2.32

PE TTM —

TSR TTM (92.50%)

Mkt cap A$30.95M

ROIC (49.07%)

SE Grade™

Value

Quality

Moat

Consensus

Reference

$0.0239

13.69%

237.49%

Hold 12|11|11|4|11

TTM

FYE 30 Jun AUD

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

5Y

10Y

Peers

2.178

Revenue$M

3.976

4.111

4.398

4.545

4.902

5.164

5.519

5.691

6.007

6.467

2.311

5.70%

5.37%

71

2.21

Revenue growth%

11.11

10.96

13.11

12.04

14.98

16.76

14.78

13.25

11.65

11.51

8.50

13.25

12.57

90

9.58

Gross margin%

28.31

29.19

27.34

28.23

28.67

29.26

29.29

30.93

29.28

29.76

14.86

29.29

29.23

82

18.75

Operating margin%

8.77

9.31

6.70

8.61

9.29

10.84

9.74

10.88

12.06

9.77

5.58

10.84

9.52

22

17.59

Net margin%

27.73

30.71

30.54

32.20

34.53

37.28

37.76

35.05

37.97

38.42

12.57

37.76

34.79

9

25.60

P/E ratio (avg)x

29.55

29.24

33.81

40.06

39.87

46.53

52.02

50.46

51.06

51.15

6.060

51.06

43.30

77

21.64

EV/EBITx

33.38

31.50

31.98

35.79

37.75

41.03

46.73

53.21

59.55

60.93

12.79

53.21

39.39

76

6.21

FCF yield (avg)%

24.10

25.96

24.47

26.42

24.67

21.68

23.86

23.09

23.72

26.15

8.20

23.72

24.29

34

8.79

FCF margin%

24.59

24.78

24.68

21.72

20.14

17.35

15.50

15.56

13.88

11.79

3.99

15.50

18.74

71

0.222

FCF / Net incomex

1.077

1.141

1.213

1.226

1.391

1.622

1.573

1.677

1.811

1.873

0.836

1.677

1.482

33

28.77

ROIC%

5.27

6.27

6.02

8.34

10.34

9.82

12.54

12.11

14.57

15.10

10.11

12.54

10.08

5

25.07

Return on equity%

29.45

27.25

26.11

26.17

23.45

25.70

27.97

28.61

29.09

31.32

8.01

28.61

27.61

14

13.87

Return on assets%

20.39

21.98

23.46

25.97

26.43

26.88

24.24

24.26

25.97

24.93

18.57

24.93

24.60

6

—

EPS$

—

—

—

—

—

—

—

—

—

—

—

0.07%

(1.12%)

—

25.42

EPS growth%

9.34

7.18

9.16

11.94

9.51

9.26

12.09

9.34

11.08

10.57

27.67

10.57

9.43

11

—

Bookvalue per sh$

—

—

—

—

—

—

—

—

—

—

—

11.06%

9.31%

—

—

FCF per share$

—

—

—

—

0.01

0.01

0.01

0.01

0.01

0.01

—

7.59%

10.22%

—

—

Dividend per sh$

—

—

—

—

—

—

—

—

—

—

—

2.14%

2.51%

—

25.50

Div yield (avg)%

4.38

3.66

3.34

3.68

4.47

5.49

8.03

10.43

10.28

10.36

4.87

10.28

4.98

93

27.78

Payout ratio%

16.85

15.67

12.73

14.02

11.30

11.64

10.86

13.18

13.62

13.05

6.23

13.05

13.12

81

1.465

Shares (diluted)B

1.376

1.459

1.331

1.355

1.246

1.115

1.150

1.126

1.049

1.166

1.516

(1.33%)

(2.35%)

53

22.28

Buyback yield%

22.15

24.82

22.41

22.35

23.79

22.67

23.50

25.09

25.69

23.63

17.03

23.63

23.57

44

0.432

D/E ratiox

0.780

0.877

1.039

1.234

1.396

1.449

1.636

1.868

2.168

2.152

1.763

1.868

1.422

12

5.624

Enterprise value$M

1.240

1.110

1.125

1.142

1.146

1.027

0.943

0.879

0.793

0.808

3.307

(6.75%)

(4.30%)

55

1.509

LT debt$M

9.592

11.21

11.83

12.20

14.60

15.33

17.06

17.73

18.68

19.17

2.474

5.60%

7.05%

32

Peers (US$21.26M)

Cap (US$)

PE

22.69M

—

Botanix Pharmaceutical…

18.97M

—

Neurotech Internationa…

17.76M

—

Atossa Therapeutics…

21.16M

—

Capital

TTM

5Y

10Y

Leveragex

1.148

(0.225)

(0.217)

EBIT/Intx

1.249

0.093

0.102

Own earn%

197.43

(92.93)

(99.13)

Sh yield%

47.77

33.99

28.37

Owners

Insiders/Inst%

1.23

29.16

Short interest%

3.61

SBC / revenue%

3.02

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

15

Op margin range%

7–12

$1 testx

—

Incr. ROIC%

5

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

$6.467M

5.37%

1.00×

Cost of revenue

$2.922M

5.58%

1.02×

Operating expenses

$1.399M

5.15%

0.98×